<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2024-384</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-8618</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CHRONIC HEART FAILURE</subject></subj-group></article-categories><title-group><article-title>Оценка фракции выброса и сократительная функция левого желудочка: насколько этот параметр точен?</article-title><trans-title-group xml:lang="en"><trans-title>Ejection fraction assessment and left ventricular contractile function: How accurate is this parameter?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5684-9842</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гвоздева</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Gvozdeva</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гвоздева Анна Дмитриевна, врач функциональной диагностики</p><p>109240, Москва, ул. Яузская, д. 11/6</p></bio><bio xml:lang="en"><p>Anna D. Gvozdeva</p><p>11/6, Yauzskaya St., Moscow, 109240</p></bio><email xlink:type="simple">gvozdevaannalech@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4027-3727</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Закиев</surname><given-names>В. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Zakiev</surname><given-names>V. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Закиев Вадим Дмитриевич, младший научный сотрудник лаборатории клинической фармакологии и фармакотерапии Российского геронтологического научно-клинического центра</p><p>129226, Москва, ул. 1-я Леонова, д. 16</p></bio><bio xml:lang="en"><p>Vadim D. Zakiev, Junior Researcher, Laboratory of Clinical Pharmacology and Pharmacotherapy, Russian Gerontological Research and Clinical Center</p><p>16, 1st Leonov St., Moscow, 129226</p></bio><email xlink:type="simple">zakiev739@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8505-1848</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гиляревский</surname><given-names>С. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Gilyarevskiy</surname><given-names>S. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гиляревский Сергей Руджерович, д.м.н., профессор, ведущий научный сотрудник лаборатории сердечно-сосудистого старения Российского геронтологического научно-клинического центра</p><p>129226, Москва, ул. 1-я Леонова, д. 16</p></bio><bio xml:lang="en"><p>Sergey R. Gilyarevskiy, Dr. Sci. (Med.), Professor, Leading Researcher, Laboratory of Cardiovascular Aging, Russian Gerontological Research and Clinical Center</p><p>16, 1st Leonov St., Moscow, 129226</p></bio><email xlink:type="simple">21sgilarevsky@rambler.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Городская клиническая больница имени И.В. Давыдовского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Davydovsky Moscow City Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н.И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>30</day><month>10</month><year>2024</year></pub-date><volume>0</volume><issue>16</issue><fpage>108</fpage><lpage>113</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гвоздева А.Д., Закиев В.Д., Гиляревский С.Р., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Гвоздева А.Д., Закиев В.Д., Гиляревский С.Р.</copyright-holder><copyright-holder xml:lang="en">Gvozdeva A.D., Zakiev V.D., Gilyarevskiy S.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/8618">https://www.med-sovet.pro/jour/article/view/8618</self-uri><abstract><p>Оценка фракции выброса (ФВ) левого желудочка (ЛЖ) относится к важным компонентам диагностики сердечной недостаточности (СН) и принятия решения о тактике лечения пациентов с СН. В клинической практике для оценки систолической функции ЛЖ и ФВ ЛЖ обычно используется эхокардиография, прежде всего в связи с ее простотой и доступностью, однако данный метод имеет ряд ограничений, к которым относят в первую очередь межисследовательскую и внутриисследовательскую вариабельность результатов, зависимость от качества визуализации и др. Результаты исследований, в ходе выполнения которых изучали эффекты применения различных лекарственных средств при СН и сохраненной ФВ ЛЖ, свидетельствовали о различиях эффективности препаратов в зависимости от величины ФВ ЛЖ. Такие результаты позволяют предположить, что препараты базовой терапии СН и сниженной ФВ ЛЖ сохраняют свою эффективность при СН и сохраненной ФВ ЛЖ, если у них имеются признаки нарушения не только диастолической, но и систолической функции. Таким образом, ФВ ЛЖ может быть недостаточно надежным критерием для выбора терапии. В связи с этим очевидна необходимость внедрения в клиническую практику дополнительных маркеров для оценки систолической функции ЛЖ. Целью данного обзора было обсуждение трудностей оценки и клинической интерпретации систолической функции ЛЖ с помощью эхокардиографии и возможностей альтернативных диагностических методов, в частности деформации миокарда (спекл-трекинг-эхокардиография).</p></abstract><trans-abstract xml:lang="en"><p>Evaluation of the left ventricular (LV) ejection fraction (EF) is a key component for diagnosis and treatment of heart failure (HF). Echocardiography is commonly used to assess LV systolic function and LV EF due to its simplicity and availability. However, it has some limitations, including interand intra-observer variability, dependence on the quality of visualization, etc. HF trials showed that there are some differences in the HF therapy effectiveness depending on the value of LV EF. These results suggest that basic therapy for HF and reduced LVEF is also effective in HF and preserved LVEF if patients have impairment of not only diastolic but also systolic function. Thus, LVEF may not be a reliable parameter to guide treatment decisions andit is necessary to introduce additional markers into clinical practice to assess LV systolic function. The purpose of this review is to discuss the difficulties of assessing LV systolic function using echocardiography and the possibilities of using alternative diagnostic methods, in particular myocardial deformation (speckle tracking echocardiography).</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фракция выброса левого желудочка</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>эхокардиография</kwd><kwd>спеклтрекинг-эхокардиография</kwd><kwd>систолическая функция миокарда</kwd><kwd>глобальная деформация миокарда</kwd></kwd-group><kwd-group xml:lang="en"><kwd>left ventricular ejection fraction</kwd><kwd>chronic heart failure</kwd><kwd>echocardiography</kwd><kwd>speckle-tracking echocardiography</kwd><kwd>left ventricular systolic function</kwd><kwd>global myocardial deformation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–e1032. https://doi.org/10.1161/CIR.0000000000001063.</mixed-citation><mixed-citation xml:lang="en">Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–e1032. https://doi.org/10.1161/CIR.0000000000001063.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368.</mixed-citation><mixed-citation xml:lang="en">McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Агеев ФТ, Арутюнов ГП, Беграмбекова ЮЛ, Беленков ЮН, Бойцов СА, Васюк ЮА и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. https://doi.org/10.15829/1560-4071-2020-4083.</mixed-citation><mixed-citation xml:lang="en">Ageev FT, Arutyunov GP, Begrambekova YuL, Belenkov YuN, Boytsov SA, Vasyuk YuA et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) https://doi.org/10.15829/1560-4071-2020-4083.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dimond MG, Ibrahim NE, Fiuzat M, McMurray JJV, Lindenfeld J, Ahmad T et al. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping. JACC Heart Fail. 2024;12(3):451–460. https://doi.org/10.1016/j.jchf.2023.11.005.</mixed-citation><mixed-citation xml:lang="en">Dimond MG, Ibrahim NE, Fiuzat M, McMurray JJV, Lindenfeld J, Ahmad T et al. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping. JACC Heart Fail. 2024;12(3):451–460. https://doi.org/10.1016/j.jchf.2023.11.005.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18(12):1301–1310. https://doi.org/10.1093/ehjci/jex244.</mixed-citation><mixed-citation xml:lang="en">Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18(12):1301–1310. https://doi.org/10.1093/ehjci/jex244.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Poppe KK, Doughty RN, Gardin JM, Hobbs FDR, McMurray JJV, Nagueh SF et al. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function: The EchoNoRMAL Study. JACC Cardiovasc Imaging. 2015;8(6):656–665. https://doi.org/10.1016/j.jcmg.2015.02.014.</mixed-citation><mixed-citation xml:lang="en">Poppe KK, Doughty RN, Gardin JM, Hobbs FDR, McMurray JJV, Nagueh SF et al. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function: The EchoNoRMAL Study. JACC Cardiovasc Imaging. 2015;8(6):656–665. https://doi.org/10.1016/j.jcmg.2015.02.014.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14. https://doi.org/10.1016/j.echo.2014.10.003.</mixed-citation><mixed-citation xml:lang="en">Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14. https://doi.org/10.1016/j.echo.2014.10.003.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Marwick TH. Ejection Fraction Pros and Cons: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(19):2360–2379. https://doi.org/10.1016/j.jacc.2018.08.2162.</mixed-citation><mixed-citation xml:lang="en">Marwick TH. Ejection Fraction Pros and Cons: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(19):2360–2379. https://doi.org/10.1016/j.jacc.2018.08.2162.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90(4):1765–1773. https://doi.org/10.1161/01.cir.90.4.1765.</mixed-citation><mixed-citation xml:lang="en">A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90(4):1765–1773. https://doi.org/10.1161/01.cir.90.4.1765.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13. Available at: https://pubmed.ncbi.nlm.nih.gov/10023943.</mixed-citation><mixed-citation xml:lang="en">The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13. Available at: https://pubmed.ncbi.nlm.nih.gov/10023943.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007. Available at: https://pubmed.ncbi.nlm.nih.gov/10376614.</mixed-citation><mixed-citation xml:lang="en">Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007. Available at: https://pubmed.ncbi.nlm.nih.gov/10376614.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G et al. Candesartan in heart failure – assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail. 1999;5(3):276–282. https://doi.org/10.1016/s1071-9164(99)90013-1.</mixed-citation><mixed-citation xml:lang="en">Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G et al. Candesartan in heart failure – assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail. 1999;5(3):276–282. https://doi.org/10.1016/s1071-9164(99)90013-1.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Otterstad JE, Froeland G, St John Sutton M, Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J. 1997;18(3):507–513. https://doi.org/10.1093/oxfordjournals.eurheartj.a015273.</mixed-citation><mixed-citation xml:lang="en">Otterstad JE, Froeland G, St John Sutton M, Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J. 1997;18(3):507–513. https://doi.org/10.1093/oxfordjournals.eurheartj.a015273.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wood PW, Choy JB, Nanda NC, Becher H. Left ventricular ejection fraction and volumes: it depends on the imaging method. Echocardiography. 2014;31(1):87–100. https://doi.org/10.1111/echo.12331.</mixed-citation><mixed-citation xml:lang="en">Wood PW, Choy JB, Nanda NC, Becher H. Left ventricular ejection fraction and volumes: it depends on the imaging method. Echocardiography. 2014;31(1):87–100. https://doi.org/10.1111/echo.12331.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lenell J, Lindahl B, Karlsson P, Batra G, Erlinge D, Jernberg T et al. Reliability of estimating left ventricular ejection fraction in clinical routine: a validation study of the SWEDEHEART registry. Clin Res Cardiol. 2023;112(1):68–74. https://doi.org/10.1007/s00392-022-02031-0.</mixed-citation><mixed-citation xml:lang="en">Lenell J, Lindahl B, Karlsson P, Batra G, Erlinge D, Jernberg T et al. Reliability of estimating left ventricular ejection fraction in clinical routine: a validation study of the SWEDEHEART registry. Clin Res Cardiol. 2023;112(1):68–74. https://doi.org/10.1007/s00392-022-02031-0.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lyng Lindgren F, Tayal B, Bundgaard Ringgren K, Ascanius Jacobsen P, Hay Kragholm K, Zaremba T et al. The variability of 2D and 3D transthoracic echocardiography applied in a general population: Intermodality, inter- and intraobserver variability. Int J Cardiovasc Imaging. 2022;38(10):2177–2190. https://doi.org/10.1007/s10554-022-02618-8.</mixed-citation><mixed-citation xml:lang="en">Lyng Lindgren F, Tayal B, Bundgaard Ringgren K, Ascanius Jacobsen P, Hay Kragholm K, Zaremba T et al. The variability of 2D and 3D transthoracic echocardiography applied in a general population: Intermodality, inter- and intraobserver variability. Int J Cardiovasc Imaging. 2022;38(10):2177–2190. https://doi.org/10.1007/s10554-022-02618-8.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Stokke TM, Hasselberg NE, Smedsrud MK, Sarvari SI, Haugaa KH, Smiseth OA et al. Geometry as a Confounder When Assessing Ventricular Systolic Function: Comparison Between Ejection Fraction and Strain. J Am Coll Cardiol. 2017;70(8):942–954. https://doi.org/10.1016/j.jacc.2017.06.046.</mixed-citation><mixed-citation xml:lang="en">Stokke TM, Hasselberg NE, Smedsrud MK, Sarvari SI, Haugaa KH, Smiseth OA et al. Geometry as a Confounder When Assessing Ventricular Systolic Function: Comparison Between Ejection Fraction and Strain. J Am Coll Cardiol. 2017;70(8):942–954. https://doi.org/10.1016/j.jacc.2017.06.046.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Klaeboe LG, Edvardsen T. Echocardiographic assessment of left ventricular systolic function. J Echocardiogr. 2019;17(1):10–16. https://doi.org/10.1007/s12574-018-0405-5.</mixed-citation><mixed-citation xml:lang="en">Klaeboe LG, Edvardsen T. Echocardiographic assessment of left ventricular systolic function. J Echocardiogr. 2019;17(1):10–16. https://doi.org/10.1007/s12574-018-0405-5.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123(18):1996–2005. https://doi.org/10.1161/circulationaha.110.981431.</mixed-citation><mixed-citation xml:lang="en">De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123(18):1996–2005. https://doi.org/10.1161/circulationaha.110.981431.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Закиев ВД, Воробьева НМ, Малая ИП, Гвоздева АД, Ткачева ОН. Бетаадреноблокаторы при хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка: возможен ли депрескрайбинг? Рациональная фармакотерапия в кардиологии. 2023;19(6):607–613. https://doi.org/10.20996/1819-6446-2023-2987.</mixed-citation><mixed-citation xml:lang="en">Zakiev VD, Vorobyeva NM, Malaya IP, Gvozdeva AD, Tkacheva ON. Betablockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible? Rational Pharmacotherapy in Cardiology. 2023;19(6):607–613. (In Russ.) https://doi.org/10.20996/1819-6446-2023-2987.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–781. https://doi.org/10.1016/S0140-6736(03)14285-7.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–781. https://doi.org/10.1016/S0140-6736(03)14285-7.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609–1620. https://doi.org/10.1056/NEJMoa1908655.</mixed-citation><mixed-citation xml:lang="en">Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609–1620. https://doi.org/10.1056/NEJMoa1908655.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038.</mixed-citation><mixed-citation xml:lang="en">Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–1098. https://doi.org/10.1056/NEJMoa2206286.</mixed-citation><mixed-citation xml:lang="en">Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–1098. https://doi.org/10.1056/NEJMoa2206286.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Агеев ФТ, Овчинников АГ, Агеева СФ, Мареев ВЮ. Что такое «нормальная фракция выброса левого желудочка» и ее связь с патогенезом и эффективностью лечения сердечной недостаточности. Кардиология. 2023;63(6):69–74. https://doi.org/10.18087/cardio.2023.6.n2404.</mixed-citation><mixed-citation xml:lang="en">Ageev FT, Ovchinnikov AG, Ageeva SF, Mareev VY. What is “normal left ventricular ejection fraction” and its relationship with the pathogenesis and effectiveness of the treatment of heart failure. Kardiologiya. 2023;63(6):69–74. (In Russ.). https://doi.org/10.18087/cardio.2023.6.n2404.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Nauta JF, Jin X, Hummel YM, Voors AA. Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal. Eur J Heart Fail. 2018;20(12):1636–1638. https://doi.org/10.1002/ejhf.1326.</mixed-citation><mixed-citation xml:lang="en">Nauta JF, Jin X, Hummel YM, Voors AA. Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal. Eur J Heart Fail. 2018;20(12):1636–1638. https://doi.org/10.1002/ejhf.1326.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Potter E, Marwick TH. Assessment of Left Ventricular Function by Echocardiography: The Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction. JACC Cardiovasc Imaging. 2018;11(2):260–274. https://doi.org/10.1016/j.jcmg.2017.11.017.</mixed-citation><mixed-citation xml:lang="en">Potter E, Marwick TH. Assessment of Left Ventricular Function by Echocardiography: The Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction. JACC Cardiovasc Imaging. 2018;11(2):260–274. https://doi.org/10.1016/j.jcmg.2017.11.017.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Negishi T, Negishi K, Thavendiranathan P, Cho GY, Popescu BA, Vinereanu D et al. Effect of Experience and Training on the Concordance and Precision of Strain Measurements. JACC Cardiovasc Imaging. 2017;10(5):518–522. https://doi.org/10.1016/j.jcmg.2016.06.012.</mixed-citation><mixed-citation xml:lang="en">Negishi T, Negishi K, Thavendiranathan P, Cho GY, Popescu BA, Vinereanu D et al. Effect of Experience and Training on the Concordance and Precision of Strain Measurements. JACC Cardiovasc Imaging. 2017;10(5):518–522. https://doi.org/10.1016/j.jcmg.2016.06.012.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang KW, French B, May Khan A, Plappert T, Fang JC, Sweitzer NK et al. Strain improves risk prediction beyond ejection fraction in chronic systolic heart failure. J Am Heart Assoc. 2014;3(1):e000550. https://doi.org/10.1161/JAHA.113.000550.</mixed-citation><mixed-citation xml:lang="en">Zhang KW, French B, May Khan A, Plappert T, Fang JC, Sweitzer NK et al. Strain improves risk prediction beyond ejection fraction in chronic systolic heart failure. J Am Heart Assoc. 2014;3(1):e000550. https://doi.org/10.1161/JAHA.113.000550.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging. 2009;2(5):356–564. https://doi.org/10.1161/CIRCIMAGING.109.862334.</mixed-citation><mixed-citation xml:lang="en">Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging. 2009;2(5):356–564. https://doi.org/10.1161/CIRCIMAGING.109.862334.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014;100(21):1673–1680. https://doi.org/10.1136/heartjnl-2014-305538.</mixed-citation><mixed-citation xml:lang="en">Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014;100(21):1673–1680. https://doi.org/10.1136/heartjnl-2014-305538.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of Myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25):2751–2768. https://doi.org/10.1016/j.jacc.2014.01.073.</mixed-citation><mixed-citation xml:lang="en">Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of Myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25):2751–2768. https://doi.org/10.1016/j.jacc.2014.01.073.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M et al. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart. 2020;106(11):817–823. https://doi.org/10.1136/heartjnl-2019-316297.</mixed-citation><mixed-citation xml:lang="en">Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M et al. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart. 2020;106(11):817–823. https://doi.org/10.1136/heartjnl-2019-316297.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International CardioOncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–4361. https://doi.org/10.1093/eurheartj/ehac244.</mixed-citation><mixed-citation xml:lang="en">Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International CardioOncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–4361. https://doi.org/10.1093/eurheartj/ehac244.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S et al. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2023;16(3):269–278. https://doi.org/10.1016/j.jcmg.2022.10.010.</mixed-citation><mixed-citation xml:lang="en">Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S et al. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2023;16(3):269–278. https://doi.org/10.1016/j.jcmg.2022.10.010.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Szelényi Z, Fazakas Á, Szénási G, Tegze N, Fekete B, Molvarec A et al. The mechanism of reduced longitudinal left ventricular systolic function in hypertensive patients with normal ejection fraction. J Hypertens. 2015;33(9):1962–1969. https://doi.org/10.1097/HJH.0000000000000624.</mixed-citation><mixed-citation xml:lang="en">Szelényi Z, Fazakas Á, Szénási G, Tegze N, Fekete B, Molvarec A et al. The mechanism of reduced longitudinal left ventricular systolic function in hypertensive patients with normal ejection fraction. J Hypertens. 2015;33(9):1962–1969. https://doi.org/10.1097/HJH.0000000000000624.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Holland DJ, Marwick TH, Haluska BA, Leano R, Hordern MD, Hare JL et al. Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. Heart. 2015;101(13):1061–1066. https://doi.org/10.1136/heartjnl2014-307391.</mixed-citation><mixed-citation xml:lang="en">Holland DJ, Marwick TH, Haluska BA, Leano R, Hordern MD, Hare JL et al. Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. Heart. 2015;101(13):1061–1066. https://doi.org/10.1136/heartjnl2014-307391.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Saito M, Okayama H, Yoshii T, Higashi H, Morioka H, Hiasa G et al. Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012;13(7):617–623. https://doi.org/10.1093/ejechocard/jer318.</mixed-citation><mixed-citation xml:lang="en">Saito M, Okayama H, Yoshii T, Higashi H, Morioka H, Hiasa G et al. Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012;13(7):617–623. https://doi.org/10.1093/ejechocard/jer318.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Liu H, Pozios I, Haileselassie B, Nowbar A, Sorensen LL, Phillip S et al. Role of Global Longitudinal Strain in Predicting Outcomes in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;120(4):670–675. https://doi.org/10.1016/j.amjcard.2017.05.039.</mixed-citation><mixed-citation xml:lang="en">Liu H, Pozios I, Haileselassie B, Nowbar A, Sorensen LL, Phillip S et al. Role of Global Longitudinal Strain in Predicting Outcomes in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017;120(4):670–675. https://doi.org/10.1016/j.amjcard.2017.05.039.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Barros-Gomes S, Williams B, Nhola LF, Grogan M, Maalouf JF, Dispenzieri A et al. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System. JACC Cardiovasc Imaging. 2017;10(4):398–407. https://doi.org/10.1016/j.jcmg.2016.04.008.</mixed-citation><mixed-citation xml:lang="en">Barros-Gomes S, Williams B, Nhola LF, Grogan M, Maalouf JF, Dispenzieri A et al. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System. JACC Cardiovasc Imaging. 2017;10(4):398–407. https://doi.org/10.1016/j.jcmg.2016.04.008.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(5):447–456. https://doi.org/10.1016/j.jacc.2013.09.052.</mixed-citation><mixed-citation xml:lang="en">Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(5):447–456. https://doi.org/10.1016/j.jacc.2013.09.052.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK et al. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. Eur J Heart Fail. 2017;19(7):893–900. https://doi.org/10.1002/ejhf.754.</mixed-citation><mixed-citation xml:lang="en">DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK et al. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. Eur J Heart Fail. 2017;19(7):893–900. https://doi.org/10.1002/ejhf.754.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Brann A, Miller J, Eshraghian E, Park JJ, Greenberg B. Global longitudinal strain predicts clinical outcomes in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2023;25(10):1755–1765. https://doi.org/10.1002/ejhf.2947.</mixed-citation><mixed-citation xml:lang="en">Brann A, Miller J, Eshraghian E, Park JJ, Greenberg B. Global longitudinal strain predicts clinical outcomes in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2023;25(10):1755–1765. https://doi.org/10.1002/ejhf.2947.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Morris DA, Ma XX, Belyavskiy E, Aravind Kumar R, Kropf M, Kraft R et al. Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Heart. 2017;4(2):e000630. https://doi.org/10.1136/openhrt-2017-000630.</mixed-citation><mixed-citation xml:lang="en">Morris DA, Ma XX, Belyavskiy E, Aravind Kumar R, Kropf M, Kraft R et al. Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Heart. 2017;4(2):e000630. https://doi.org/10.1136/openhrt-2017-000630.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2015;16(1):1–11. https://doi.org/10.1093/ehjci/jeu184.</mixed-citation><mixed-citation xml:lang="en">Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2015;16(1):1–11. https://doi.org/10.1093/ehjci/jeu184.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
